LexaGene’s Prototype for Better Pathogen Detection Now Capable of Identifying E. coli and Staph
Summary
BEVERLY, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- With the recent outbreaks associated with romaine lettuce ( E. coli ) and eggs ( Salmonella ) in the headlines, LexaGene Holdings Inc. (OTCQB:LXXGF (TSXV:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that its prototype for more effective pathogen detection is now generating data, including the ability to identify E. coli and Staph .“Generating data with the prototype is a monumental milestone for the Company, especially given that we are at such a critical moment in society right now with new foodborne illnesses happening so frequently,” said Dr. Jack Regan, LexaGene’s CEO.The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation.Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Companys expectations as disclosed in the Companys documents filed from time to time on SEDAR (see www.sedar.com ).